Evidence map›Paper›PMID 29889662›Full record

ReviewCurrent opinion in HIV and AIDS2018

Progress in achieving long-term HIV remission.

Maria Pino, Mirko Paiardini, Vincent C Marconi

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in HIV and AIDS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Maria PinoYerkes National Primate Research Center (YNPRC), Emory Vaccine Center (EVC), Emory University.
Mirko PaiardiniYerkes National Primate Research Center (YNPRC), Emory Vaccine Center (EVC), Emory University.
Vincent C MarconiYerkes National Primate Research Center (YNPRC), Emory Vaccine Center (EVC), Emory University.
Emory University · USAtlanta VA Medical Center · US

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Ann M Chahroudi, Colleen F Kelley · 2002 to 2026
$74.0M
Central memory CD4 T cell infection: key role in ART response and HIV persistenceR01AI110334 · NIAID · EMORY UNIVERSITY · PI MARCONI, VINCENT CHARLES, PAIARDINI, MIRKO · 2013 to 2017
$4.4M
Immune based interventions for HIV eradicationR01AI116379 · NIAID · EMORY UNIVERSITY · PI PAIARDINI, MIRKO · 2015 to 2019
$4.2M
NIAID NIH HHS P30 AI050409NIAID NIH HHS R01 AI110334NIAID NIH HHS R01 AI116379
6 · The paper itself

Abstract

purpose of reviewThe purpose of the present review is to describe the major barriers to HIV eradication and assess the most promising cure strategies under investigation. RECENT

findingsThere are significant challenges to achieve HIV eradication. These include the establishment of persistent latently infected cells, systemic chronic immune activation, and immune dysfunction. Since the announcement of the first HIV cure involving the Berlin patient, several attempts to reproduce these results have failed. Thus, it is widely accepted that long-term HIV remission would be a more feasible approach. Optimization of ART, immune-based therapies, therapeutic vaccinations, and gene editing, amongst others, are strategies aimed at controlling HIV in the absence of ART. These new strategies alone or in combination are being developed in preclinical studies and clinical trials and will provide further insight into whether long-term HIV remission is possible. SUMMARY: The present review discusses several mechanisms that mediate the persistence of the HIV reservoir, clinical cases that provide hope in finding a functional cure of HIV, and promising interventional strategies being tested in preclinical studies and clinical trials that attempt to reduce the HIV reservoirs and/or boost the immune responses to control HIV in the absence of ART.

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsHumansRemission InductionAnti-HIV Agents

Identifiers

PMID29889662
PMCPMC8696266
OpenAlexW2806934489

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.